Roberts · Brain : a journal of neurology 2017 · Post-mortem case-control tissue analysis and imaging correlation study · n=?

Biochemically-defined pools of amyloid-β in sporadic Alzheimer's disease: correlation with amyloid PET.

Cited 144 times in the scientific literature.

Level 4 - case-series / case-control

Post-mortem case-control tissue study combined with imaging modeling

PubMed 28383676 · doi:10.1093/brain/awx057 · record verified 2026-08-31

What was done

Frontal cortical grey matter from human Alzheimer's disease patients and control subjects was fractionated into four biochemically defined pools: soluble/cytosolic, peripheral membrane/vesicular cargo, integral lipid/membranous, and aggregated/insoluble debris. Amyloid-β distribution and exchange across compartments were quantified. The researchers combined these biochemical measurements with MRI volumetric analysis and amyloid PET standard uptake value ratio (SUVR) data to calculate total brain amyloid-β mass and estimate accumulation rates over time.

What was found

Most readily extractable amyloid-β was associated with the lipid/membranous compartment. Inter-pool exchange was lost specifically for amyloid-β42 in Alzheimer's disease. Total brain amyloid-β was estimated at 6.5 mg in Alzheimer's disease versus 1.7 mg in controls. A PET SUVR threshold of 1.4 corresponded to 5.0 μg amyloid-β/g grey matter, while the mean Alzheimer's disease dementia SUVR of 2.3 equated to 11.20 μg/g. The accumulation window between these thresholds was calculated as 19 years, yielding an estimated net accumulation rate of 28 ng/h (4.8 mg difference), accounting for 2% to 5% of total amyloid-β production.

Why it matters

This study provides an absolute quantitative calibration linking clinical amyloid PET imaging to physical tissue concentrations of amyloid-β. It demonstrates that pathological accumulation occurs at a very low rate (28 ng/h) over decades, providing quantitative benchmarks for therapeutics targeting amyloid clearance.

Limits

The abstract does not state the sample size (n) or demographic details of the Alzheimer's disease and control groups. Kinetic accumulation estimates over 19 years are based on cross-sectional modeling rather than direct longitudinal tissue sampling. Tissue analysis was restricted to frontal cortical grey matter.

Cited by